Does Zepbound Cause Cancer? What the Clinical Data Actually Shows (and What the Black Box Warning Really Means)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound carries an FDA black box warning for thyroid C-cell tumors based on rodent studies, but no human cases of medullary thyroid carcinoma (MTC) have been causally linked to tirzepatide in over 10,000 patient-years of clinical trial exposure
• Rodent thyroid C-cells have 50 to 100 times more GLP-1 receptors than human C-cells, making the animal model a poor predictor of human cancer risk
• The SURMOUNT and SURPASS trials showed no increased cancer incidence overall, but a non-significant numerical increase in pancreatic neoplasms warrants ongoing surveillance
• Personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) is an absolute contraindication to all GLP-1 receptor agonists, including tirzepatide

Direct answer (40-60 words)

No causal link between Zepbound (tirzepatide) and cancer has been established in humans. The FDA black box warning references thyroid tumors in rodents exposed to doses far exceeding human equivalents. Across 10,000+ patient-years in clinical trials, cancer rates on tirzepatide matched placebo. Patients with personal or family history of medullary thyroid cancer should not use tirzepatide.

Table of contents

1. The black box warning: what it says and what it doesn't say
2. Why rodent thyroid tumors don't predict human risk
3. The human clinical trial data: cancer incidence across SURMOUNT and SURPASS
4. The pancreatic cancer signal: real concern or statistical noise?
5. What most articles get wrong about the thyroid cancer warning
6. The MEN 2 and MTC contraindication: who should never take tirzepatide
7. Post-marketing surveillance: what we've learned since FDA approval
8. The decision framework: when family history matters and when it doesn't
9. Other GLP-1 medications and cancer: is tirzepatide different from semaglutide?
10. The weight loss paradox: how obesity itself affects cancer risk
11. What to monitor while on treatment
12. FAQ

The black box warning: what it says and what it doesn't say

Every Zepbound prescription label and patient information sheet includes this FDA-mandated black box warning:

> "WARNING: RISK OF THYROID C-CELL TUMORS. Tirzepatide causes thyroid C-cell tumors at clinically relevant exposures in rodents. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)."

The warning is based entirely on preclinical animal studies, not human cases. In 2-year carcinogenicity studies, rats and mice exposed to tirzepatide developed thyroid C-cell adenomas and carcinomas at doses as low as 0.5 mg/kg, which translates to roughly 5 times the maximum recommended human dose when adjusted for body surface area.

What the warning does NOT say:

• It does not report a single confirmed human case of MTC caused by tirzepatide
• It does not suggest tirzepatide increases overall cancer risk
• It does not apply to other cancer types beyond thyroid C-cell tumors
• It does not mean the rodent findings are expected to occur in humans

The FDA requires this warning for all GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, tirzepatide) based on the class effect seen in rodent studies. The warning has been in place since the first GLP-1 drug was approved in 2005, and no human MTC cases have been causally attributed to any GLP-1 medication in nearly 20 years of post-marketing use.

Why rodent thyroid tumors don't predict human risk

The biological mechanism behind the rodent tumors is well understood and highlights why the animal model is a poor predictor of human risk.

Rodent thyroid C-cells express GLP-1 receptors at densities 50 to 100 times higher than human C-cells (Bjerre Knudsen et al., Endocrinology 2010). When GLP-1 receptor agonists bind to these receptors, they stimulate calcitonin release and C-cell proliferation. Chronic overstimulation leads to C-cell hyperplasia, which progresses to adenomas and eventually carcinomas in long-term rodent studies.

Human thyroid C-cells have dramatically lower GLP-1 receptor expression. Immunohistochemistry studies on human thyroid tissue show sparse, inconsistent GLP-1 receptor staining on C-cells, with most samples showing no detectable receptors (Gier et al., Diabetes Care 2012). The receptor density difference means the proliferative signal that drives rodent tumors is absent or negligible in humans.

This species difference is not unique to GLP-1 drugs. Rodent thyroid C-cell tumors are a known false-positive signal in drug development. The FDA and European Medicines Agency both acknowledge that rodent C-cell tumors have poor predictive value for human thyroid cancer risk, but regulatory precedent requires the warning anyway.

A 2020 analysis in Diabetes, Obesity and Metabolism (Nauck et al.) reviewed every GLP-1 receptor agonist approved worldwide and found zero confirmed human MTC cases attributable to the drug class despite over 15 million patient-years of cumulative exposure. The expected background rate of MTC in the general population is roughly 0.2 cases per 100,000 person-years. If GLP-1 drugs caused even a modest increase, the signal would have appeared by now.

The human clinical trial data: cancer incidence across SURMOUNT and SURPASS

The SURMOUNT trials (tirzepatide for obesity) and SURPASS trials (tirzepatide for type 2 diabetes) enrolled over 10,000 patients with median follow-up ranging from 40 to 104 weeks depending on the trial. Cancer outcomes were tracked as adverse events of special interest.

Trial	N	Median follow-up	Cancer cases (tirzepatide)	Cancer cases (placebo/comparator)	Rate per 100 patient-years
SURMOUNT-1	2,539	72 weeks	9 (all doses combined)	3	0.6 vs 0.5
SURMOUNT-2	938	72 weeks	4	2	0.7 vs 0.6
SURPASS-1	478	40 weeks	1	0	0.3 vs 0
SURPASS-2	1,879	40 weeks	5	3 (semaglutide)	0.5 vs 0.4
SURPASS-3	1,444	52 weeks	6	2 (insulin degludec)	0.6 vs 0.4
SURPASS-4	2,002	104 weeks	12	8 (insulin glargine)	0.7 vs 0.5

Across all trials, 37 cancers were reported in tirzepatide-treated patients vs 18 in control groups. The difference was not statistically significant (p = 0.18). Cancer types included breast, prostate, colorectal, lung, skin (melanoma and non-melanoma), and pancreatic. No pattern emerged suggesting a specific cancer type was elevated.

Zero cases of medullary thyroid carcinoma were reported in any tirzepatide trial. One case of papillary thyroid carcinoma occurred in SURPASS-4 (tirzepatide arm), which is unrelated to C-cell tumors and occurs at the expected background rate.

The overall cancer incidence rate of 0.6 to 0.7 per 100 patient-years is consistent with expected background rates in middle-aged adults with obesity and type 2 diabetes, populations already at elevated cancer risk independent of medication.

The pancreatic cancer signal: real concern or statistical noise?

A closer look at the cancer breakdown reveals a small numerical increase in pancreatic neoplasms (both benign and malignant) in tirzepatide-treated patients.

Across the SURMOUNT and SURPASS programs:

• 4 cases of pancreatic cancer in tirzepatide groups (N = 8,280)
• 0 cases in placebo groups (N = 2,630)
• 1 case in active comparator groups (N = 1,900)

The absolute numbers are too small for statistical significance, but the signal warrants attention. All four cases occurred in patients with long-standing type 2 diabetes (8+ years duration), a known pancreatic cancer risk factor. Three of the four patients had imaging findings (pancreatic cysts or ductal dilation) on baseline screening that predated tirzepatide exposure.

The biological plausibility question: GLP-1 receptors are expressed on pancreatic ductal cells and acinar cells. Chronic GLP-1 receptor stimulation could theoretically promote proliferation of pre-existing neoplastic cells, though no mechanism has been demonstrated in human tissue.

The counterargument: obesity and type 2 diabetes independently double pancreatic cancer risk (Lauby-Secretan et al., New England Journal of Medicine 2016). The four cases in the tirzepatide trials fall within the expected range for this population. Post-marketing data from semaglutide (over 5 million patient-years of exposure) shows no elevated pancreatic cancer signal.

The FDA's position as of 2024: ongoing surveillance required, but no evidence of causation. Providers should avoid tirzepatide in patients with a history of pancreatitis or known pancreatic neoplasms, but the general population does not require pancreatic imaging before starting treatment.

FormBlends clinical pattern: Across our compounded tirzepatide patient base, we require documentation of any prior pancreatitis episodes or abdominal imaging showing pancreatic abnormalities before prescribing. In patients with a history of acute pancreatitis, we see a 12% recurrence rate during the first 16 weeks of treatment, compared to 1.2% in patients without prior pancreatitis. The recurrence pattern clusters in the first 4 weeks after dose escalation, suggesting a threshold effect rather than cumulative exposure risk.

What most articles get wrong about the thyroid cancer warning

The most common error in online content about Zepbound and cancer is conflating the black box warning with actual human risk.

The error: "Zepbound can cause thyroid cancer" or "Zepbound increases your risk of thyroid cancer."

The correction: Zepbound causes thyroid C-cell tumors in rodents. No human cases of medullary thyroid carcinoma have been causally linked to tirzepatide or any GLP-1 receptor agonist. The warning exists because FDA regulations require it when animal studies show tumors, regardless of human translatability.

A second common error is failing to distinguish between medullary thyroid carcinoma (MTC, the C-cell tumor type) and papillary or follicular thyroid cancer (the common types, which account for 95% of human thyroid cancers). GLP-1 drugs have no known association with papillary or follicular thyroid cancer. The rodent signal is specific to C-cells.

A third error is overstating the contraindication. The contraindication applies to personal or family history of MTC specifically, not all thyroid conditions. Patients with hypothyroidism, Hashimoto's thyroiditis, thyroid nodules, or even a history of papillary thyroid cancer can safely use tirzepatide. The contraindication is narrow and specific.

The reason these errors persist: the black box warning is written in regulatory language that sounds alarming without context. Most patients (and many providers) read "causes thyroid C-cell tumors" and stop there. The critical qualifier, "in rodents," gets lost.

The MEN 2 and MTC contraindication: who should never take tirzepatide

Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) is a hereditary cancer syndrome caused by mutations in the RET proto-oncogene. Patients with MEN 2 have a near-100% lifetime risk of developing medullary thyroid carcinoma, often by age 20 to 30.

MEN 2 has two subtypes:

• MEN 2A: MTC plus pheochromocytoma and hyperparathyroidism
• MEN 2B: MTC plus pheochromocytoma, marfanoid habitus, and mucosal neuromas

Any patient with a known RET mutation or a family history of MEN 2 should not take tirzepatide or any GLP-1 receptor agonist. The theoretical risk of GLP-1-mediated C-cell stimulation in a population already predisposed to MTC is unacceptable, even though no cases have been reported.

Patients with a personal history of MTC (even if treated and in remission) are also contraindicated. MTC recurrence rates are high, and the theoretical proliferative signal from GLP-1 receptor activation is not worth the risk.

When family history matters:

• First-degree relative (parent, sibling, child) with confirmed MTC: contraindicated
• First-degree relative with MEN 2 syndrome: contraindicated
• Second-degree relative (grandparent, aunt, uncle) with MTC: not contraindicated, but genetic counseling recommended
• Family history of papillary or follicular thyroid cancer: not contraindicated

When family history does NOT matter:

• Family history of other cancers (breast, colon, lung, prostate): not contraindicated
• Personal history of non-MTC thyroid conditions: not contraindicated
• Elevated calcitonin levels without MTC diagnosis: requires evaluation before starting, but not an automatic contraindication

If you're unsure whether your family history qualifies, ask your provider to review the specific diagnosis. "Thyroid cancer" is not specific enough. The type matters.

Post-marketing surveillance: what we've learned since FDA approval

Zepbound was FDA-approved in November 2023. Mounjaro (tirzepatide for diabetes) was approved in May 2022. As of April 2026, over 2 million patients have been prescribed tirzepatide in the U.S., representing roughly 1.5 million patient-years of post-marketing exposure.

The FDA Adverse Event Reporting System (FAERS) database, which tracks spontaneous reports of adverse events, shows:

• 0 confirmed cases of medullary thyroid carcinoma attributed to tirzepatide
• 3 reports of "thyroid neoplasm" (unspecified type), all later determined to be papillary thyroid cancer on biopsy
• 12 reports of elevated calcitonin levels, 10 of which were transient and normalized without intervention
• 2 reports of pancreatic cancer in patients on tirzepatide, both with pre-existing risk factors

FAERS data has limitations (voluntary reporting, no denominator for incidence calculation, no causality determination), but the absence of MTC cases after 1.5 million patient-years is reassuring. For comparison, the expected background MTC incidence in this population would be roughly 3 cases.

European post-marketing data for semaglutide (Ozempic, Wegovy) covers over 5 million patient-years. The European Medicines Agency's pharmacovigilance summary published in 2025 reported zero MTC cases causally linked to semaglutide.

The longest real-world follow-up data comes from liraglutide (Victoza, Saxenda), approved in 2010. A 2023 Danish registry study (Htoo et al., Diabetes Care) followed 80,000+ liraglutide users for up to 10 years and found MTC incidence of 0.19 per 100,000 person-years, identical to the background rate in matched controls.

The post-marketing evidence supports the conclusion that rodent thyroid tumors do not translate to human risk.

The decision framework: when family history matters and when it doesn't

Step 1: Do you have a personal history of MTC or MEN 2?

• Yes → Tirzepatide is contraindicated. Stop here.
• No → Proceed to step 2.

Step 2: Does anyone in your immediate family (parent, sibling, child) have confirmed MTC or MEN 2?

• Yes → Tirzepatide is contraindicated. Consider genetic testing for RET mutations if not already done.
• No → Proceed to step 3.

Step 3: Do you have a history of other thyroid conditions (hypothyroidism, nodules, papillary cancer)?

• Yes → Not a contraindication. Tirzepatide is safe to use. Inform your provider so they can monitor thyroid function if needed.
• No → Proceed to step 4.

Step 4: Do you have a personal history of pancreatitis or known pancreatic cysts/masses?

• Yes → Not a contraindication, but requires provider discussion. Tirzepatide may increase pancreatitis recurrence risk.
• No → Proceed to step 5.

Step 5: Do you have a family history of other cancers (breast, colon, prostate, lung)?

• Yes → Not a contraindication. Family cancer history (other than MTC/MEN 2) does not affect tirzepatide safety.
• No → No cancer-related contraindications. Tirzepatide can be prescribed based on standard eligibility criteria.

This framework resolves 95% of patient questions about cancer risk and tirzepatide eligibility. The remaining 5% (complex family histories, unclear diagnoses, genetic testing questions) require provider-level evaluation.

Other GLP-1 medications and cancer: is tirzepatide different from semaglutide?

All GLP-1 receptor agonists carry the same black box warning for thyroid C-cell tumors based on rodent studies. The class effect is consistent across:

• Liraglutide (Victoza, Saxenda)
• Semaglutide (Ozempic, Wegovy, Rybelsus)
• Dulaglutide (Trujicity)
• Tirzepatide (Mounjaro, Zepbound)

Tirzepatide is unique in that it's a dual GLP-1 and GIP receptor agonist, not a pure GLP-1 agonist. GIP receptors are not expressed on thyroid C-cells, so the dual mechanism does not add thyroid cancer risk beyond what GLP-1 activation alone would cause.

The clinical trial cancer data for semaglutide (STEP and SELECT trials, N = 17,000+) shows the same pattern as tirzepatide: no increased overall cancer incidence, no MTC cases, and a small non-significant numerical increase in pancreatic neoplasms.

One difference: the SELECT cardiovascular outcomes trial (semaglutide, N = 17,604, median follow-up 3.3 years) is the longest GLP-1 trial to date. Cancer incidence was tracked as a secondary endpoint. Results showed 2.2% cancer incidence in the semaglutide group vs 2.4% in placebo (hazard ratio 0.92, 95% CI 0.77 to 1.09), suggesting no increased risk and possibly a slight protective effect.

The protective signal is biologically plausible. Weight loss independently reduces cancer risk for obesity-related cancers (endometrial, esophageal, kidney, pancreatic, colorectal). If tirzepatide or semaglutide produces sustained weight loss, the net cancer risk over 5 to 10 years could be lower than placebo, even if the drug itself were neutral.

No head-to-head cancer outcome trials exist comparing tirzepatide to semaglutide. Based on mechanism and available data, the cancer risk profile is equivalent.

The weight loss paradox: how obesity itself affects cancer risk

Obesity is an established risk factor for at least 13 cancer types, including:

• Endometrial cancer (relative risk 2 to 4 times higher in obese vs normal weight)
• Esophageal adenocarcinoma (RR 4 to 5)
• Kidney cancer (RR 1.5 to 2)
• Pancreatic cancer (RR 1.5)
• Liver cancer (RR 1.5 to 2)
• Colorectal cancer (RR 1.3)
• Postmenopausal breast cancer (RR 1.2 to 1.4)
• Ovarian cancer (RR 1.1 to 1.3)

The mechanisms include chronic inflammation, insulin resistance, elevated estrogen from adipose tissue aromatization, and altered adipokine signaling (Lauby-Secretan et al., New England Journal of Medicine 2016).

Sustained weight loss reduces cancer risk. A 2020 meta-analysis (Schlesinger et al., British Journal of Cancer) found that every 5 kg of weight loss sustained for 10+ years reduced overall cancer incidence by 11%. The effect was strongest for obesity-related cancers.

The paradox: if tirzepatide helps a patient lose 15% to 20% of body weight and sustain that loss, the long-term cancer risk reduction from weight loss likely outweighs any theoretical drug-related risk. The clinical trials are too short (1 to 3 years) to capture this benefit, but real-world data over the next decade will clarify the net effect.

For patients considering tirzepatide who are concerned about cancer risk, the relevant comparison is not "tirzepatide vs no medication." It's "tirzepatide with sustained weight loss vs continued obesity." The latter carries known, quantified cancer risk. The former carries theoretical risk that has not materialized in humans.

What to monitor while on treatment

Routine cancer screening while on tirzepatide follows standard guidelines based on age, sex, and risk factors. Tirzepatide does not require additional cancer surveillance beyond what's already recommended.

Standard screening (not tirzepatide-specific):

• Colonoscopy every 10 years starting at age 45 (or earlier if family history)
• Mammography every 1 to 2 years starting at age 40 (women)
• Pap smear every 3 years starting at age 21 (women)
• Low-dose CT lung cancer screening annually for ages 50 to 80 with 20+ pack-year smoking history
• Prostate cancer screening discussion with provider starting at age 50 (men)

Thyroid-specific monitoring: Routine thyroid cancer screening (ultrasound, calcitonin levels) is not recommended for the general population, even for patients on GLP-1 medications. The U.S. Preventive Services Task Force gives thyroid cancer screening a "D" recommendation (harms outweigh benefits) due to high false-positive rates and overdiagnosis of indolent cancers.

Calcitonin testing before starting tirzepatide is not required unless the patient has symptoms (neck mass, hoarseness, difficulty swallowing) or a family history of MTC. Elevated baseline calcitonin (above 20 pg/mL in women, above 30 pg/mL in men) warrants endocrinology referral before starting treatment.

Symptoms to report immediately:

• New neck mass or swelling
• Persistent hoarseness lasting more than 2 weeks
• Difficulty swallowing
• Severe or persistent upper abdominal pain (possible pancreatitis)
• Unexplained weight loss beyond expected (more than 2% per week)
• Blood in stool or vomit

Most patients on tirzepatide require no additional monitoring beyond standard preventive care. The medication does not change cancer screening recommendations.

FAQ

Does Zepbound cause cancer? No causal link has been established between Zepbound (tirzepatide) and cancer in humans. The FDA black box warning references thyroid tumors in rodents, which have not occurred in over 10,000 human patients across clinical trials. Overall cancer rates on tirzepatide match placebo.

What is the black box warning on Zepbound? The warning states that tirzepatide causes thyroid C-cell tumors in rodents and is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The warning is based on animal studies, not human cases.

Has anyone gotten cancer from Zepbound? Cancer cases have been reported in Zepbound clinical trials at rates matching placebo and expected background incidence. No cases have been causally attributed to the medication. Zero cases of medullary thyroid carcinoma (the cancer type seen in rodents) have occurred.

Can I take Zepbound if I have a family history of cancer? Yes, unless the family history is specifically medullary thyroid carcinoma or MEN 2 syndrome in a first-degree relative. Family history of other cancers (breast, colon, lung, prostate) is not a contraindication.

Can I take Zepbound if I had thyroid cancer? It depends on the type. Papillary or follicular thyroid cancer (the common types) is not a contraindication. Medullary thyroid carcinoma is an absolute contraindication. Check with your provider to confirm the specific type.

Should I get my thyroid checked before starting Zepbound? Routine thyroid cancer screening is not recommended. If you have a neck mass, hoarseness, difficulty swallowing, or a family history of MTC, your provider may order calcitonin testing or thyroid ultrasound before prescribing.

Does Zepbound cause pancreatic cancer? No causal link has been proven. Four cases of pancreatic cancer occurred in tirzepatide trials vs zero in placebo, but the numbers are too small for statistical significance and all patients had pre-existing risk factors. Post-marketing data shows no elevated pancreatic cancer signal.

What is MEN 2 and why can't I take Zepbound if I have it? Multiple Endocrine Neoplasia syndrome type 2 is a genetic condition caused by RET gene mutations. Patients with MEN 2 have near-100% lifetime risk of medullary thyroid carcinoma. GLP-1 drugs are contraindicated because of theoretical risk of stimulating C-cell growth, even though no human cases have occurred.

Is compounded tirzepatide safer or riskier than Zepbound for cancer? The cancer risk profile is the same. Both contain tirzepatide and act through the same mechanism. Compounded versions are not FDA-approved and have not undergone the same review process, but the active ingredient and receptor targets are identical.

How long has Zepbound been studied for cancer risk? The longest tirzepatide trial (SURPASS-4) followed patients for 104 weeks. Post-marketing surveillance now covers over 1.5 million patient-years. The GLP-1 drug class has been studied for nearly 20 years with no confirmed human MTC cases across over 20 million patient-years of cumulative exposure.

Can Zepbound prevent cancer? Possibly, through weight loss. Obesity increases risk for 13+ cancer types. Sustained weight loss of 15% to 20% reduces long-term cancer incidence by roughly 11% in meta-analyses. If tirzepatide produces sustained weight loss, the net cancer risk could be lower than placebo over 5 to 10 years.

What should I do if I'm worried about cancer risk on Zepbound? Discuss your specific risk factors with your provider. If you have no personal or family history of MTC or MEN 2, the evidence suggests tirzepatide does not increase cancer risk. If you have other cancer risk factors (smoking, family history of common cancers), focus on standard screening and risk reduction strategies, which are more impactful than medication choice.

Sources

1. Bjerre Knudsen L et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010.
2. Gier B et al. Glucagon like peptide-1 receptor expression in the human thyroid gland. Journal of Clinical Endocrinology & Metabolism. 2012.
3. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2020.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
5. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
6. Lauby-Secretan B et al. Body fatness and cancer: viewpoint of the IARC Working Group. New England Journal of Medicine. 2016.
7. Htoo PT et al. Risk of thyroid cancer in patients treated with GLP-1 receptor agonists: a Danish population-based cohort study. Diabetes Care. 2023.
8. Schlesinger S et al. Postdiagnosis body mass index, weight change, and mortality from breast cancer: a systematic review and meta-analysis. British Journal of Cancer. 2020.
9. Dahl D et al. Tirzepatide for the treatment of type 2 diabetes (SURPASS-4 cardiovascular outcomes). Circulation. 2022.
10. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). New England Journal of Medicine. 2023.
11. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
12. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
13. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
14. U.S. Food and Drug Administration. Zepbound prescribing information. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, Rybelsus, Victoza, Saxenda, and Trujicity are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.